Haspel at Mike Pompeo's swearing in as Secretary of State. Photo: Mandel Ngan/AFP via Getty Images

Gina Haspel, President Trump's nominee to succeed Mike Pompeo as CIA director, wanted to withdraw her name from consideration amid concerns that her role in enhanced interrogation of suspected terrorists would derail with her confirmation, Axios has confirmed, per a source with direct knowledge. The story was first reported by The Washington Post.

The details: During a West Wing meeting with White House officials on Friday, Haspel indicated that she planned to withdraw to avoid "the spectacle of a brutal confirmation hearing," per the Post. That prompted press secretary Sarah Sanders and legislative affairs director Marc Short to head to CIA headquarters to convince her to keep her name in consideration.

  • "Amid the questioning in the West Wing on Friday afternoon, Haspel told White House aides she did not want her nomination to harm the CIA. She also feared unfair attacks on her own reputation, saying that she didn’t want to be 'the next Ronny Jackson,' one official said."
  • "Trump learned of the drama Friday, calling officials from his trip to Dallas. He decided to push for Haspel to remain as the nominee after initially signaling he would support whatever decision was taken, administration officials said."
  • "Short ... told Haspel she could still be confirmed despite the information that had recently come to attention of the White House — and the administration expected some Democrats to support her, officials said."

Go deeper: Meet Gina Haspel ... The CIA's history with "black sites" and "enhanced interrogation."

Get more stories like this by signing up for our weekly political lookahead newsletter, Axios Sneak Peek. 

Go deeper

The childless vaccine

Illustration: Eniola Odetunde/Axios

It'll likely be a long time before children are vaccinated against COVID-19, even though vaccinating kids could eventually play an integral role in reducing the virus' spread.

The big picture: None of the leading contenders in the U.S. are being tested for their effectiveness in children. Even once one of them gains authorization from the Food and Drug Administration, there will only be a limited number of available doses.

Progressives bide time for a Biden victory

Illustration: Sarah Grillo/Axios

Progressive Democrats want to beat President Trump so badly that they're tabling their apathy about Joe Biden — organizing hard to get him into office, only to fight him once elected.

Why it matters: That's a big difference from 2016, when progressives’ displeasure with Hillary Clinton depressed turnout and helped deliver the White House to Trump.

Election influence operations target journalists

Illustration: Aïda Amer/Axios

Foreign and domestic actors looking to influence the 2020 election are trying to trick real reporters into amplifying fake storylines. This tactic differs from 2016, when bad actors used fake accounts and bots to amplify disinformation to the population directly.

Why it matters: The new strategy, reminiscent of spy operations during the Cold War, is much harder for big tech platforms to police and prevent.